Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC_EX:A61K39/44

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/130546HUMAN CLK2 PROTEIN-DERIVED CELL MEMBRANE-PENETRATING DOMAIN
WO 25.06.2020
Int.Class A61K 39/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
44Antibodies bound to carriers
Appl.No PCT/KR2019/017828 Applicant KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY Inventor KIM, Seong Jun
The present invention relates to a human CLK2 protein-derived cell membrane-penetrating domain and, more particularly, to a human CLK2 protein-derived cell membrane-penetrating domain (CLK2P cell membrane-penetrating domain) or cell-penetrating peptide, and an intracellular delivery system using same. The human CLK2 protein-derived cell membrane-penetrating domain of the present invention can be delivered intracellularly and cargo substances such as compounds, biomolecules, and various polymer materials can be delivered intracellularly using same. The CLK2P cell membrane-penetrating domain of the present invention exhibits higher cell-penetrating efficiency than that of conventional cell-penetrating peptides and is derived from human protein, and thus can prevent the occurrence of side effects and immune responses that are caused by exogenous protein-derived peptides, and accordingly, can be effectively used as a method for effectively delivering, into cells, compounds, biomolecules, and various polymer materials, which are to be applied to a human body.
2.WO/2020/123662FUSION PROTEIN CONSTRUCTS FOR COMPLEMENT ASSOCIATED DISEASE
WO 18.06.2020
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No PCT/US2019/065741 Applicant ADMIRX INC. Inventor CURTIS, Michael Steven
Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.
3.WO/2020/122741TERNARY MICELLAR COMPLEX COMPOSED OF A SIALOGLYCOSPHINGOLIPID, A THERAPEUTICALLY ACTIVE SUBSTANCE AND AN ANTIBODY
WO 18.06.2020
Int.Class A61K 9/107
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
107Emulsions
Appl.No PCT/PE2018/000033 Applicant CONSEJO NACIONAL DE INVESTIGACIONES CIENTÍFICAS Y TÉCNICAS (CONICET) Inventor BELTRAMO, Dante Miguel
The invention relates to a pharmaceutical composition soluble in an aqueous solution, which is characterised in that it comprises sialoglycosphingolipids; polypeptides selected from the group comprising antibodies, fragments and variants of same; and at least one therapeutically active substance, forming a ternary micellar complex of sialoglycosphingolipid–therapeutically active substance–polypeptide in which the polypeptides are non-covalently associated with the micelles formed by the sialoglycosphingolipid and the therapeutically active substance.
4.WO/2020/113047ANTIBODIES CONJUGATED WITH ACTINIUM-225 AND ACTINIUM-227, AND RELATED COMPOSITIONS AND METHODS
WO 04.06.2020
Int.Class A61K 51/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51Preparations containing radioactive substances for use in therapy or testing in vivo
02characterised by the carrier
04Organic compounds
08Peptides, e.g. proteins
10Antibodies or immunoglobulins; Fragments thereof
Appl.No PCT/US2019/063668 Applicant ACTINIUM PHARMACEUTICALS, INC. Inventor LUDWIG, Dale
This invention provides a compositions of matter comprising a therapeutic protein population (such as a HuM195 antibody population) wherein (a) each therapeutic protein in the population is conjugated to one or more actinium atoms, (b) each actinium atom is either 227Ac or 225Ac, and (c) the molar ratio of 227Ac to 225Ac in the composition is at least 1:1, This invention also provides related synthetic compositions and methods, as well as methods for treating hematologic malignancies.
5.WO/2020/103910POLYPEPTIDE FOR TREATING PATHOLOGICAL BLOOD CLOTS
WO 28.05.2020
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Appl.No PCT/CN2019/120004 Applicant IMMUNWORK INC. Inventor CHANG, Tse-Wen
The present disclosure provides a polypeptide including an anti-fibrin antibody and a serine protease moiety of human tissue plasminogen activator. Methods for treating thrombosis in a subject in need of such treatment using such polypeptide are also disclosed.
6.WO/2020/102324LIQUIDLY INJECTABLE, SELF-STABILIZING BIOPOLYMERS FOR THE DELIVERY OF RADIONUCLIDE
WO 22.05.2020
Int.Class A61K 49/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
49Preparations for testing in vivo
06Nuclear magnetic resonance (NMR) contrast preparations; Magnetic resonance imaging (MRI) contrast preparations
08characterised by the carrier
10Organic compounds
14Peptides, e.g. proteins
Appl.No PCT/US2019/061144 Applicant DUKE UNIVERSITY Inventor CHILKOTI, Ashutosh
Described herein are compositions for liquidly injectable, self-stabilizing biopolymers for the delivery of radionuclide brachytherapy. Also described herein are methods of using the compositions.
7.WO/2020/102609COMPOSITIONS AND METHODS FOR THE CYTOPLASMIC DELIVERY OF ANTIBODIES AND OTHER PROTEINS
WO 22.05.2020
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2019/061575 Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor TSOURKAS, Andrew
The invention provides compositions and methods for the cytoplasmic delivery of antibodies and other proteins. Specifically, provided herein are compositions having an anionic polypeptide and a cationic transfection agent for facilitating the cytoplasmic delivery of an antibody or a protein.
8.WO/2020/097139CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
WO 14.05.2020
Int.Class A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Appl.No PCT/US2019/059954 Applicant MERCK SHARP & DOHME CORP. Inventor ANTOCHSHUK, Valentyn
The present invention provides co-formulations of anti-PD-1 antibodies and anti-LAG3 antibodies, and their use in treating various disorders.
9.3650038IN VIVO TARGETING OF CELLS WITH LIGAND-CONJUGATED PARTICLES
EP 13.05.2020
Int.Class A61K 38/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
20Interleukins
Appl.No 19189418 Applicant MASSACHUSETTS INST TECHNOLOGY Inventor IRVINE DARRELL J
The invention provides compositions and methods for,inter alia,augmenting cell-based therapiesin vivoby repeatedly stimulating target cells of interest over a period of time.
10.111110638一种偶联有蛋白的微球冻干制剂及其制备方法、保存方式
CN 08.05.2020
Int.Class A61K 9/19
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders
19lyophilised
Appl.No 202010027383.7 Applicant 广州市丹蓝生物科技有限公司 Inventor 赵峰
本发明公开了一种偶联有蛋白的微球冻干制剂及其制备方法、保存方式,微球冻干制剂包括冻干保护剂和偶联有蛋白的微球;冻干保护剂包括溶剂和溶质,溶剂为0.1~0.2mol/L的磷酸盐缓冲液;以溶剂的体积计,溶质为:动物血清:1~10%(v/v);海藻糖:1~10%(w/v);聚乙烯吡咯烷酮:0.2~5%(w/v);葡聚糖:0.2~5%(w/v);甘露醇:3%~10%(w/v);Proclin300:0.01~0.1%(v/v);冻干保护剂的pH值为7.4±0.5;偶联有蛋白的微球冻干制剂由冻干保护剂和偶联有蛋白的微球混合后冻干获得。采用本发明的冻干制剂,能够显著提高偶联有蛋白的微球的稳定性。